- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.09. | OSR Holdings verstößt gegen NASDAQ-Mindestkursanforderung | - | Investing.com Deutsch | ||
| 09.09. | OSR Holdings receives Nasdaq notice for minimum bid price non-compliance | 1 | Seeking Alpha | ||
| 09.09. | OSR Holdings receives Nasdaq minimum bid price deficiency notice | 2 | Investing.com | ||
| 09.09. | OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity | 71 | PR Newswire | BELLEVUE, Wash., Sept. 9, 2025 /PRNewswire/ -- OSR Holdings (Nasdaq: OSRH) today announced that on September 5, 2025, it received a written notification from... ► Artikel lesen | |
| OSR HOLDINGS Aktie jetzt für 0€ handeln | |||||
| 09.09. | OSR Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.08. | OSR Holdings ändert Vereinbarungen mit White Lion Capital und beruft Hauptversammlung ein | 2 | Investing.com Deutsch | ||
| 20.08. | OSR Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08. | OSR Holdings, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 06.08. | OSR Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 31.07. | OSR Holdings informiert über Eigenkapitalfinanzierung und Aktienausgabe | 2 | Investing.com Deutsch | ||
| 31.07. | OSR Holdings updates on equity financing, shares issued under ELOC | 1 | Investing.com | ||
| 30.07. | OSR Holdings advances acquisition of Korean glucose monitoring firm | 1 | Investing.com | ||
| 30.07. | OSR Holdings Inc.: OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure | 138 | PR Newswire | BELLEVUE, Wash. and SEOUL, South Korea, July 30, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and... ► Artikel lesen | |
| 25.07. | OSR Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.07. | Gambling Commission responds to OSR recommendations following GSGB review | 2 | iGaming Business | ||
| 24.07. | OSR Holdings enters term sheet to acquire Woori IO | 1 | Seeking Alpha | ||
| 24.07. | OSR Holdings signs term sheet to acquire noninvasive glucose tech firm | 1 | Investing.com | ||
| 24.07. | OSR Holdings Inc.: OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology | 115 | PR Newswire | BELLEVUE, Wash. and SEOUL, South Korea, July 24, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and... ► Artikel lesen | |
| 15.07. | OSR appoints Andreas Niethammer as Chief Medical Officer of Vaximm AG | 1 | Seeking Alpha | ||
| 15.07. | OSR Holdings appoints Andreas Niethammer as CMO of Vaximm AG | 3 | Investing.com |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ENLIVEN THERAPEUTICS | 18,960 | -5,01 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks... ► Artikel lesen | |
| QIAGEN | 39,005 | +0,26 % | QIAGEN N.V.: QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio | Full portfolio of QIAstat-Dx panels now CE-IVDR certified for use in clinical syndromic testing, underscoring commitment to highest-quality diagnostics CE-IVDR clearance granted for QIAstat-Dx... ► Artikel lesen | |
| EVOTEC | 6,272 | -0,32 % | Kurs von Evotec steigt etwas (5,966 €) | Im Plus liegt zur Stunde die Aktie von Evotec . Das Wertpapier notiert derzeit bei 5,97 Euro. Im deutschen Wertpapierhandel hat sich heute die Aktie von Evotec zwischenzeitlich um 2,54 Prozent verteuert.... ► Artikel lesen | |
| HUMACYTE | 1,860 | +3,91 % | Humacyte Plans To File IND For Coronary Tissue Engineered Vessel In Q4 | ||
| RECURSION PHARMACEUTICALS | 4,910 | -0,41 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| NUVALENT | 76,64 | -5,34 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results |
Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| BIONTECH | 82,00 | +0,06 % | Edelmetalle im Check: Rheinmetall | Biontech | Magna - Platin besser als Gold? | Rheinmetall übernimmt die Marinesparte von Lürssen. Der DAX-Konzern stärkt mit dem Kauf seine Position im Marinesektor. Analysten taxieren den Preis auf 1,5 bis 2 Milliarden €. Anleger schicken die... ► Artikel lesen | |
| 89BIO | 14,860 | -0,67 % | Milliarden-Pharma-Übernahme: Roche kauft sich in Biotech-Milliardenmarkt ein - 89bio im Fokus | © Foto: SOPA Images - Sipa USARoche kauft das US-amerikanische Biotech-Unternehmen 89bio für bis zu 3,5 Milliarden US-Dollar. Im Fokus steht ein Hoffnungsträger gegen die Fettleberkrankheit MASH, ein... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 6,200 | -2,21 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results | CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren's disease BCMA-directed bispecific T cell engager velinotamig... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 41,090 | -1,72 % | Roth/MKM initiates Avidity Biosciences stock with Buy rating on platform potential | ||
| SUMMIT THERAPEUTICS | 18,860 | -1,92 % | Summit Therapeutics stock rating reiterated at Buy by H.C. Wainwright | ||
| ADMA BIOLOGICS | 15,910 | -1,55 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 49,130 | -3,97 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses | ||
| TARSUS PHARMACEUTICALS | 55,00 | +1,78 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| TOURMALINE BIO | 47,700 | +0,04 % | BMO Capital downgrades Tourmaline Bio stock rating following Novartis acquisition news |
OSR HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,15 % bei einem Aktienkurs von 0,724 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OSR HOLDINGS INC finden Sie auf Wallstreet Online.